Mackenbach JP, Bouvier-Colle MH, Jougla E. “Avoidable” mortality and health services: a review of aggregate data studies. J Epidemiol Community Health [Internet]. 1990 Jun [cited 2012 Jun 27];44(2):106–1Available from: http://www.ncbi.nlm.nih.gov/pubmed/2196328
Carbonneil C, Donkova-Petrini V, Aouba A, Weiss L. Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4+CD25+ T cells restore high levels of HIV-specific CD4+ T cell responses induced by dendritic cells generated in the presence of IFN-alpha. J Immunol. 2004 Jun 15;172(12):7832–40.
Bouvier AM, Remontet L, Jougla E, Launoy G, Grosclaude P, Buémi A, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol. 2004 Oct;28(10 Pt 1):877–81.
Peng J, Ménégoz F, Lesec’h JM, Remontet L, Grosclaude P, Buémi A, et al. [Larynx cancer in France: descriptive epidemiology and incidence estimation]. Bull Cancer. 2004 Apr;91(4):363–8.
Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004 Jul 15;101(2):317–24.
Lienhart A, Auroy Y, Péquignot F, Benhamou D, Warszawski J, Bovet M, et al. [Preliminary results from the SFAR-iNSERM inquiry on anaesthesia-related deaths in France: mortality rates have fallen ten-fold over the past two decades]. Bull Acad Natl Med. 2004;188(8):1429–37; discussion 1437-1441.
Jougla E, Rican S, Péquignot F, Le Toullec A. [Socio-economic differences in mortality]. Rev Prat. 2004 Dec 31;54(20):2228–32.
Mertes PM, Alla F, Tréchot P, Auroy Y, Jougla E, Groupe d’Etudes des Réactions Anaphylactoïdes Peranesthésiques. Anaphylaxis during anesthesia in France: an 8-year national survey. J Allergy Clin Immunol. 2011 Aug;128(2):366–73.
Brandel JP, Welaratne A, Salomon D, Capek I, Vaillant V, Aouba A, et al. Can mortality data provide reliable indicators for Creutzfeldt-Jakob disease surveillance? A study in France from 2000 to 2008. Neuroepidemiology. 2011;37(3–4):188–92.
Gordon PH, Artaud F, Aouba A, Laurent F, Meininger V, Elbaz A. Changing mortality for motor neuron disease in France (1968-2007): an age-period-cohort analysis. Eur J Epidemiol. 2011 Sep;26(9):729–37.
Zatoński WA, HEM project team. Epidemiological analysis of health situation development in Europe and its causes until 1990. Ann Agric Environ Med. 2011 Dec;18(2):194–202.
Bouillon K, Haddy N, Delaloge S, Garbay JR, Garsi JP, Brindel P, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol. 2011 Jan 25;57(4):445–52.
Rogel A, Belot A, Suzan F, Bossard N, Boussac M, Arveux P, et al. Reliability of recording uterine cancer in death certification in France and age-specific proportions of deaths from cervix and corpus uteri. Cancer Epidemiol. 2011 Jun;35(3):243–9.
Bouvier-Colle MH, Saucedo M, Deneux-Tharaux C, CNEMM. [The confidential enquiries into maternal deaths, 1996-2006 in France: what consequences for the obstetrical care?]. J Gynecol Obstet Biol Reprod (Paris). 2011 Apr;40(2):87–102.
Nelson DE, Jarman DW, Rehm J, Greenfield TK, Rey G, Kerr WC, et al. Alcohol-attributable cancer deaths and years of potential life lost in the United States. Am J Public Health. 2013 Apr;103(4):641–8.
Hoffmann R, Plug I, Khoshaba B, McKee M, Mackenbach JP, AMIEHS working group. Amenable mortality revisited: the AMIEHS study. Gac Sanit. 2013 Jun;27(3):199–206.
Menvielle G, Rey G, Jougla E, Luce D. Diverging trends in educational inequalities in cancer mortality between men and women in the 2000s in France. BMC Public Health. 2013 Sep 10;13(1):823.
Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005. Int J Public Health. 2013 Aug 29;
Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in medical care and mortality trends from four circulatory diseases between 1970 and 2005. Eur J Public Health. 2013 Oct;23(5):852–7.
Marijon E, Tafflet M, Antero-Jacquemin J, El Helou N, Berthelot G, Celermajer DS, et al. Mortality of French participants in the Tour de France (1947-2012). Eur Heart J. 2013 Oct;34(40):3145–50.
Rafnsson SB, Bhopal RS, Agyemang C, Fagot-Campagna A, Harding S, Hammar N, et al. Sizable variations in circulatory disease mortality by region and country of birth in six European countries. Eur J Public Health. 2013 Aug;23(4):594–605.
Ghosn W, Kassie D, Jougla E, Rican S, Rey G. Spatial interactions between urban areas and cause-specific mortality differentials in France. Health Place. 2013 Nov;24:234–41.
Ghosn W, Kassié D, Jougla E, Salem G, Rey G, Rican S. Trends in geographic mortality inequalities and their association with population changes in France, 1975-2006. Eur J Public Health. 2013 Oct;23(5):834–40.
Mackenbach JP, Hoffmann R, Khoshaba B, Plug I, Rey G, Westerling R, et al. Using “amenable mortality” as indicator of healthcare effectiveness in international comparisons: results of a validation study. J Epidemiol Community Health. 2013 Feb;67(2):139–46.
Lewden C, Bonnet F, Bevilacqua S, Heripret L, May T, Morlat P, et al. [Causes of death in HIV-infected French drug users, 1995-2000]. Ann Med Interne (Paris). 2002 Nov;153(7 Suppl):2S4-10.
Clergue F, Auroy Y, Pequignot F, Jougla E, Lienhart A, Laxenaire MC. Evolution of the anaesthetic workload--the French experience. Best Pract Res Clin Anaesthesiol. 2002 Sep;16(3):459–73.